Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease ( COPD ). The Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target interleukin-4-receptor alpha ( IL-4R ).
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3M
▼ -99.8% YoY
Net Income (TTM)
-$69M
▼ -255.0% YoY
Op. Margin
-2384.49%
▼ -90654.4pp YoY
ROIC
-131.20%
▼ -49.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$61M
▼ -112.0% YoY
Op. Cash Flow (TTM)
-$61M
▼ -116.9% YoY
Net Debt
-$31M
Net Cash Position
Cash & Equiv.
$31M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with CNTB
Connect Biopharma Holdings (CNTB) in four numbers
Questions about Connect Biopharma Holdings
Is Connect Biopharma Holdings (CNTB) overvalued?
At $0.78, Connect Biopharma Holdings' price is 98% above the $0.39 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Connect Biopharma Holdings' fair value?
Intrinsiqq's calculator puts Connect Biopharma Holdings' fair value at $0.39 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 10.6, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.30. Every input can be changed on the Intrinsic Value tab.
Is Connect Biopharma Holdings a high-quality business?
Connect Biopharma Holdings scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$31M, and its weakest is return on capital at -131.2%. The Quality tab shows every check against its target.
Does Connect Biopharma Holdings (CNTB) pay a dividend?
No. Connect Biopharma Holdings (CNTB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CNTB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CNTB
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.